

#3/A
5-22-01
M.L.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wei *et al.*

Appl. No.: To Be Assigned

(*Divisional of 09/006,353, filed January 13, 1988*)

Filed: Herewith

For: **Tumor Necrosis Factor Receptor 5**

Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty. Docket: 1488.1280006/EKS/EJH

Preliminary Amendment

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

In advance of prosecution, please amend the application as follows.

In the Claims

Please cancel claims 1-22 without prejudice to or disclaimer of the subject matter thereof.

Please add the following claims 23-¹¹⁶~~23~~:

-- 23. An isolated polypeptide comprising a first amino acid sequence at least 90%

identical to a second amino acid sequence selected from the group consisting of:

*A1
Cont.*

- (a) amino acids -26 to 233 of SEQ ID NO:2;
- (b) amino acids -25 to 233 SEQ ID NO2; and
- (c) amino acids 1 to 233 SEQ ID NO2.

24. The polypeptide of claim 23, wherein said second amino acid sequence is (a).